Literature DB >> 23387529

Comparison of the diagnostic value of procalcitonin and C-reactive protein after hematopoietic stem cell transplantation: a systematic review and meta-analysis.

Y-X Lyu1, X-C Yu, M-Y Zhu.   

Abstract

OBJECTIVE: To conduct a systematic review and meta-analysis of the performance of the procalcitonin (PCT) diagnostic test for identifying infectious complications after hematopoietic stem cell transplantation (HSCT).
METHODS: We searched EMBASE, MEDLINE, the Cochrane database, and reference lists of relevant articles, with no language restrictions, through December 2011. We selected original articles that reported diagnostic performance of PCT alone or compared with other biomarkers for identifying serious infections in HSCT recipients. We quantitatively evaluated test accuracy parameters with the use of forest plots, hierarchical summary receiver operating characteristic curves, and bivariate random effect models.
RESULTS: We found 6 qualifying studies (studying 1344 episodes of suspected infection with confirmed infectious episodes) from 3 countries. These 6 studies examined both PCT and C-reactive protein (CRP) test performance. Bivariate pooled sensitivity, specificity, positive likelihood ratios, and negative likelihood ratios were 0.66 (95% confidence interval [CI] 0.60-0.72), 0.72 (95% CI 0.65-0.79), 2.39 (95% CI 1.84- 3.09), and 0.47 (95% CI 0.39-0.57) for PCT, and 0.80 (95% CI 0.54-0.93), 0.73 (95% CI 0.56-0.86), 3.00 (95% CI 1.86-4.84), and 0.27 (95% CI 0.11-0.65) for CRP. In terms of area under the curve (AUC), CRP was superior to PCT in detecting infectious complications, with an AUC of 0.82 for CRP versus an AUC of 0.69 for PCT.
CONCLUSION: The pooled accuracy estimates of 6 different studies indicated only a moderate rule-out diagnostic value of both PCT and CRP in discriminating infection from other inflammatory complications following allogeneic HSCT.
© 2013 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23387529     DOI: 10.1111/tid.12055

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  6 in total

1.  Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease.

Authors:  I García-Cadenas; I Rivera; R Martino; A Esquirol; P Barba; S Novelli; G Orti; J Briones; S Brunet; D Valcarcel; J Sierra
Journal:  Bone Marrow Transplant       Date:  2016-09-05       Impact factor: 5.483

2.  Comparison of procalcitonin and C-reactive protein as early diagnostic marker for the identification of transplant-related adverse events after allogeneic hematopoietic stem cell transplantation in pediatric patients.

Authors:  Karin Melanie Cabanillas Stanchi; Manon Queudeville; Carmen Malaval; Judith Feucht; Patrick Schlegel; Markus Dobratz; Christian Seitz; Ingo Müller; Peter Lang; Rupert Handgretinger; Michaela Döring
Journal:  J Cancer Res Clin Oncol       Date:  2019-08-24       Impact factor: 4.322

3.  The clinical value of biomarkers in respiratory complications in hematopoietic SCT.

Authors:  C M Lucena; M Rovira; A Gabarrús; X Filella; C Martínez; R Domingo; A Torres; C Agustí
Journal:  Bone Marrow Transplant       Date:  2016-10-31       Impact factor: 5.483

Review 4.  [Which biomarkers for diagnosis and guidance of anti-infection treatment in sepsis?]

Authors:  Johannes Ehler; Christoph Busjahn; Tobias Schürholz
Journal:  Anaesthesist       Date:  2021-11-12       Impact factor: 1.041

Review 5.  C-reactive protein as a prognostic factor for human osteosarcoma: a meta-analysis and literature review.

Authors:  Jian-Hua Yi; Dong Wang; Zhi-Yong Li; Jun Hu; Xiao-Feng Niu; Xiao-Lin Liu
Journal:  PLoS One       Date:  2014-05-06       Impact factor: 3.240

6.  Serum procalcitonin as an independent diagnostic markers of bacteremia in febrile patients with hematologic malignancies.

Authors:  Mina Yang; Seung Jun Choi; Jaewoong Lee; Dong Gun Lee; Yoon-Joo Kim; Yeon-Joon Park; Eun-Jee Oh
Journal:  PLoS One       Date:  2019-12-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.